Professor Hans Stauss

Job title

Head of clinical immunology and appointed governor representing University College London

Qualifications

MD, D.M.Sci, US diploma, PhD, FRCPath
 

GMC Number

6132690

Contact details

Phone number: 020 7794 0500 ext 33321

Email address: h.stauss@ucl.ac.uk

PA/secretary phone number: 020 7794 0500 ext 36662

PA/secretary email address: m.sait@ucl.ac.uk

Related services

Immunology

Biography

Professor Hans J. Stauss is the head of clinical immunology at the Royal Free Hospital. His main focus is the analysis of antigen-specific T lymphocyte responses to tumours and the development of immunotherapy approaches for treatment of cancer and chronic infection.

Hans is the director of the Institute of Immunity and Transplantation, co-director of the UCL Division of Infection and Immunity and chair for the Infection, Immunity and Inflammation Programme at UCL Partners. He was also appointed to the council of governors in April 2012.

Publications

  • King, J., Thomas, S., Corsi, F., Gao, L., Dina, R., Gillmore, R., Pigott, K., Kaisary, A., Stauss,HJ. *  Waxman J.* IL15 can reverse the unresponsiveness of Wilms’ tumor antigen-specific CTL in patients with prostate cancer. Clin Cancer Res. 2009 Feb 15;15(4):1145-54. *Joint senior authors.
  • Wright, G.P., Clare A. Notley, C.A., Xue, S.A., Bendle, G.M., Holler, A., Schumacher, T.N., Michael R. Ehrenstein, M.R., Stauss, H.J. Adoptive therapy with redirected primary regulatory T cells results in antigen-specific suppression of arthritis. Proc. Natl. Acad. Sci. USA. 2009 Nov 10;106(45):19078-83
  • Dai MS, Nitcheu-Tefit J, Alcock S, Ramirez-Jimenez F, Chao TY, Baril P, Rocha M, Brett SJ, Stauss HJ, Vassaux G.; Development of an Escherichia coli Expressing Listeriolysin-O Vaccine Against Wilms Tumor Gene 1-expressing Tumors. J Immunother. 2009 Sep 11. [Epub ahead of print]
  • Xue, S., Gao, L., Thomas, S., Hart, D.P., Xue, J.Z., Gillmore, R., Voss, R.H., Morris, E. & Stauss, H.J. Development of a WT1-TCR for clinical trials: Engineered patient T cells can eliminate autologous leukemia blasts in NOD/SCID mice. Heamatologica; 2010 Jan;95(1):126-34
  • Perro, M., Tsang, J., Xue, SH., Escors, D., Cesco-Gaspere,M., Pospori,C., Gao,L., Hart, D., Collins, M., Stauss, HJ. and Morris, E. Generation of antigen-specific multi-functional human T cells by lentiviral TCR gene transfer. Gene Ther. 2010 Jun;17(6):721-32
  • Cellerai C, Harari A, Stauss H, Yerly S, Geretti AM, Carroll A, Yee T, Ainsworth J, Williams I, Sweeney J, Freedman A, Johnson M, Pantaleo G, Kinloch-de Loes S.Early and prolonged antiretroviral therapy is associated with an HIV-1-specific T-cell profile comparable to that of long-term non-progressors.  PLoS One. 2011 Apr 5;6(4):e18164
  • Gehring AJ, Xue SA, Ho ZZ, Teoh D, Ruedl C, Chia A, Koh S, Lim SG, Maini MK, Stauss HJ, Bertoletti A. Engineering Virus-specific T cells that Target HBV Infected Hepatocytes and Hepatocellular Carcinoma Cell Lines.  J Hepatol. 2011 Jul;55(1):103-10
  • Pospori, C SA Xue, SA.,  A Holler, A., C Voisine, C., Perro, M., King, J., Fallah-Arani, F., Flutter, B., R Chakraverty, R., Stauss, HJ* and Morris, EC* (*joint senior authors). Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination. Blood, 2011 Jun 23;117(25):6813-24
  • Thomas S, Xue SA, Bangham C, Jakobsen BK, Morris E, Stauss HJ.  Human T cells expressing affinity matured TCR display accelerated responses but fail to recognise low density of MHC/peptide antigen. Blood. 2011,  Jul 14;118(2):319-29
  • Ahmadi, M., King, JW., Xue, SA., Voisine, C., Holler, A., Wright, GP., Waxman, J., Morris, EC., Stauss, HJ. CD3 limits the Efficacy of TCR Gene Therapy in vivo. Blood. 2011, Sep 29;118(13):3528-37
  • Simpson AA, Mohammed F, Salim M, Tranter A, Rickinson AB, Stauss HJ, Moss PA, Steven NM, Willcox BE. Structural and energetic evidence for highly peptide-specific tumor antigen targeting via allo-MHC restriction. Proc Natl Acad Sci U S A. 2011 Dec 27;108(52):21176-81
  • Lopez-Herrera G, Tampella G, Pan-Hammarström Q, Herholz P, Trujillo-Vargas CM, Phadwal K, Simon AK, Moutschen M, Etzioni A, Mory A, Srugo I, Melamed D, Hultenby K, Liu C, Baronio M, Vitali M, Philippet P, Dideberg V, Aghamohammadi A, Rezaei N, Enright V, Du L, Salzer U, Eibel H, Pfeifer D, Veelken H, Stauss HJ, Lougaris V, Plebani A, Gertz EM, Schäffer AA, Hammarström L, Grimbacher B. Deleterious Mutations in LRBA Are Associated with a Syndrome of Immune Deficiency and Autoimmunity. Am J Hum Genet. 2012, 90(6):986-1001
  • Xue, SA, Gao, L, Ahmadi, M, Ghorashian, S, Pospori, C, Holler, A, Wright, G, Thomas, S, Topp, M, Morris, EC, Stauss, HJ. Human MHC class I-restricted CD4+ T cells specific for Epstein-Barr Virus and Cytomegalovirus provide protective immunity in vivo. Oncoimmunology. 2013 Jan 1;2(1):e22590